Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
12:32pm, Wednesday, 04'th Mar 2026
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer Forecasts €9.6B--€10.1B Profit as Roundup Litigation Uncertainty Persists
12:25pm, Wednesday, 04'th Mar 2026
Bayer (BAYRY) shares came under pressure in Frankfurt after the German agriculture and health company outlined a 2026 outlook that suggests profit and sales cou
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
12:06pm, Wednesday, 04'th Mar 2026
BAYRY posts in-line Q4 earnings but revenues miss on lower Xarelto and Eylea sales. 2026 sales guidance signals steady growth ahead.
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
08:00am, Wednesday, 04'th Mar 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance
Bayer Net Loss Widens on Weedkiller Litigation Charges
02:02am, Wednesday, 04'th Mar 2026
The agriculture and pharmaceutical company reported a steeper net loss, including a €3.55 billion hit mainly from litigation-related expenses.
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
10:41am, Tuesday, 03'rd Mar 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
09:40am, Monday, 02'nd Mar 2026
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.
Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows
11:51am, Wednesday, 25'th Feb 2026
Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25
Bayer Sues J&J Over 51% Claim
06:16am, Tuesday, 24'th Feb 2026
Bayer (BAYRY) is taking Johnson and Johnson (JNJ) to court, accusing the healthcare giant of overstating the survival benefit of its prostate cancer drug Erleada
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
10:43am, Monday, 23'rd Feb 2026
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
10:28am, Monday, 23'rd Feb 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of
Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season
10:00am, Monday, 23'rd Feb 2026
ST. LOUIS--(BUSINESS WIRE)--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginni
Voyageur Pharmaceuticals Announces Collaboration with Bayer
08:20am, Monday, 23'rd Feb 2026
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-gr
